This is the authors' abstract. We don't add key points for this paper.
This prespecified secondary analysis shows that, when added to usual care, liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mann et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: